Amphastar Pharmaceuticals, Inc. (AMPH) Return on equity 2016–2025
Amphastar Pharmaceuticals, Inc. (AMPH) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
12.4%FY2025 · since FY2016: 3.0% → 12.4%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 12.4% | -9.3 pp |
| FY2024 | 21.8% | +0.3 pp |
| FY2023 | 21.5% | +4.2 pp |
| FY2022 | 17.3% | +3.3 pp |
| FY2021 | 13.9% | +13.6 pp |
| FY2020 | 0.3% | -12.5 pp |
| FY2019 | 12.8% | +14.6 pp |
| FY2018 | -1.7% | -2.8 pp |
| FY2017 | 1.1% | -1.9 pp |
| FY2016 | 3.0% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AMPH financial trends
AMPH RevenueAMPH Net incomeAMPH Net marginAMPH Gross profitAMPH Gross marginAMPH Operating incomeAMPH Operating marginAMPH Operating cash flowAMPH Free cash flowAMPH Capital expendituresAMPH Stock buybacksAMPH Dividends paidAMPH Total assetsAMPH Total liabilitiesAMPH Shareholders’ equityAMPH overview →